Precision medicine for IPF
Vincent Cottin and Luca Richeldi discuss the importance of precision medicine for IPF
VC: So, maybe you can tell us a little bit about precision medicine because that's a word that I’ve never heard before.
LR: It’s called in different names in different countries, in the UK it would be more stratified medicine, in the US would be more precision medicine, but the bottom line is to try to get the right drug to the right patient at the right time. Which is, kind of, the future of medicine.
And this has three major components which also apply to IPF. First is genes, the genetics is important, the second component which is important is the environment and the third component, of course, is lifestyle.
So, the idea is that we will be able in the future to target precisely some specific drug to some specific topics of patients and then this is also going down to phenotyping patients. As we know, IPF is a heterogeneous disease, probably more heterogeneous than other diseases and we know that our patients, they have different clinical behaviour, different characteristics and also different needs.
So, in terms of precision medicine for IPF I don't think we are there yet, but I guess that's definitely the way to go.